CYTO Archives - BioTuesdays

Developments

Altamira Therapeutics provides business update

Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...

April 12, 2022

Developments

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

The International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming Altamira Therapeutics’ (NASDAQ:CYTO) positive research findings regarding the in vitro efficacy and safety of its drug...

April 11, 2022

Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter...

March 15, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Developments

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment in Part B of the Phase 2 TRAVERS clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The company expects to release top-line...

February 14, 2022

Developments

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and...

February 9, 2022

Developments

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics (NASDAQ:CYTO) entered into an agreement with Avernus Pharma of Dubai for the marketing and distribution of Bentrio, Altamira’s nasal spray for protection against airborne viruses and...

February 7, 2022

Developments

Altamira Therapeutics establishes OTC Consumer Health business unit

Altamira Therapeutics (NASDAQ:CYTO) established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio, its nasal spray for the protection against airborne viruses and allergens. OTC...

February 4, 2022

Tag - CYTO

Altamira Therapeutics provides business update

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics establishes OTC Consumer Health business unit

General

More